

## OUR WORK



- Large-scale extraction & analysis of data on DMARD safety, efficacy and socio-economics in Europe
- Clinical trial “**Bio Test**” to optimize DMARD selection for RA patients using prospectively acquired tissue & blood material
- Clinical trial “**MethMax**” to optimize the dose & route of methotrexate uptake by RA patients
- Clinical trial “**RA-DRUM**” to determine if pro-active therapeutic drug monitoring can improve the effectiveness of subcutaneous biological DMARDs
- Can Torque-Teno-Virus (TTV), a new promising biomarker, be used as a predictive factor for RA patients?
- Stakeholder strategy evaluations, recruit & attribute patients research partners to maximize the implementation of SQUEEZE’s new discoveries
- Dissemination, communication and exploitation of SQUEEZE to maximize its awareness & impact among various stakeholders

## HOW WE CAN COLLABORATE (NAT. SOCIETIES OF RHEUMATOLOGY)

### Co-Branding and Joint Dissemination Activities

- Newsletter contributions*
- Contributions to your seminars/workshop*
- Presence of our topics/experts at your conference*

### Scientific and Educational Content

- Access to Research Updates (Simplified research digests tailored for clinical audiences)*

### Stakeholder Engagement and Patient Impact

- Patient-focused communication: lay summaries or patient information materials.*
- Surveys and needs assessments: identify clinician needs, practice gaps, or barriers to DMARD optimization.*
- Policy dialogue: jointly advocate with health authorities or reimbursement bodies using real-world findings.*

### Visibility and Recognition

- Acknowledgment as Key Partners (website, social media)*
- Visibility in EU Circles (support your European engagement goals)*

*A Horizon Europe-funded consortium that aims to improve **Rheumatoid Arthritis** care through **precision medicine, patient-centered approaches, and optimizing existing treatments.***



*The Squeeze consortium*

## WHO WE ARE (IN NUMBERS)

- ✓ 15 partners from 10 countries all over Europe
- ✓ Data from >30,000 patients
- ✓ 12M € Budget
- ✓ 3 Clinical Trials

## OUR AIMS

- Optimize DMARD selection based on biomarkers
- Improve efficacy and safety of existing therapies
- Enhance patient adherence through personalized care



## Want to know more? Follow us!



and visit our website:



## Contact

[contact@squeeze-project.eu](mailto:contact@squeeze-project.eu)